PRPF8

Across TCGA pan-cancer cohorts, PRPF8 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PRPF8 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher PRPF8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRPF8 expression acts as an unfavorable survival marker, although some lineages such as UCEC and ESCA show a favorable association.

SCLC, UCEC, and UCS are the cancer types where PRPF8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.137	0.700	<.001	36	view →
UCEC	DFS	Median	All	0.930	0.610	.001	36	view →
UCS	DFS	Median	All	0.163	0.529	.033	6	view →
ESCA	DFS	Median	III,IV	0.890	0.375	.021	4	view →
PRAD	DFS	Median	All	0.154	0.777	<.001	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SKCM	OS	Median	III,IV	0.402	0.734	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PRPF8–SCLC (OS)

Open the SCLC breakdown →